CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 25, 2005
Result type: Reports
Project Number: SR0043-000
Product Line: Reimbursement Review

Generic Name: Efalizumab

Brand Name: Raptiva

Manufacturer: Serono Canada Inc.

Therapeutic Area: Psoriasis, moderate to severe chronic plaque

Indications: Psoriasis, moderate to severe chronic plaque

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 24, 2006

Recommendation Type: List with clinical criteria and/or conditions